EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Cited by (1,066)

Items 701–800 of 1,066

1. High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
   Heounjeong Go, Yoon Kyung Jeon, Hyo Jin Park, Sook-Whan Sung, Jeong‐Wook Seo, Doo Hyun Chung · 2010 · Journal of Thoracic Oncology
2. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
   Robert Jr. Roskoski · 2014 · Pharmacological Research
3. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
   Raoof, Sana, Mulford, Iain J., Frisco-Cabanos, Heidie, Nangia, Varuna, Timonina, Daria, Labrot, Emma, Hafeez, Nafeeza, Bilton, Samantha J., Drier, Yotam, Ji, Fei et al. · 2019 · Oncogene
4. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR
   Watanabe, Masaru, Kawaguchi, Tomoya, Isa, Shun-ichi, Ando, Masahiko, Tamiya, Akihiro, Kubo, Akihito, Saka, Hideo, Takeo, Sadanori, Adachi, Hirofumi, Tagawa, Tsutomu et al. · 2015 · Clinical Cancer Research
5. Estrogen receptor signaling pathways in human non-small cell lung cancer
   Diana C. Márquez‐Garbán, Hsiao‐Wang Chen, Michael C. Fishbein, Lee Goodglick, Richard J. Pietras · 2007 · Steroids
6. Biological and clinical implications of EGFR mutations in lung cancer
   Tetsuya Mitsudomi, Takayuki Kosaka, Yasushi Yatabe · 2006 · International Journal of Clinical Oncology
7. Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
   Stéphanie Héon, Beow Yong Yeap, Gregory Joseph Britt, Daniel Botelho Costa, Michael S. Rabin, David Michael Jackman, Bruce Evan Johnson · 2010 · Clinical Cancer Research
8. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
   Mothaffar Fahed Rimawi, Priya Bhatia Shetty, Heidi L. Weiss, Rachel Schiff, Charles Kent Osborne, Gary C. Chamness, Richard M. Elledge · 2010 · Cancer
9. The Evolving War on Cancer
   Daniel A. Haber, Nathanael S. Gray, Jose M Baselga · 2011 · Cell
10. Phosphoproteomic analysis of Her2/neu signaling and inhibition
    Ron Bose, Henrik Molina, Angelica Patterson, J. Kipchirchir Bitok, Balamurugan Periaswamy, Joel S. Bader, Akhilesh Pandey, Philip A. Cole · 2006 · Proceedings of the National Academy of Sciences
11. Posttranslational Protein Modifications
    Karl E. Krueger, Sudhir Srivastava · 2006 · Molecular & Cellular Proteomics
12. Cancer pharmacogenomics: strategies and challenges
    Heather E. Wheeler, Michael L. Maitland, M. Eileen Dolan, Nancy Jean Cox, Mark J. Ratain · 2012 · Nature Reviews Genetics
13. Precision medicine in non-small cell lung cancer: Current applications and future directions
    Soo‐Ryum Yang, Anne Maria Schultheis, Helena Alexandra Yu, Diana L. Mandelker, Marc Ladanyi, Reinhard Büttner · 2020 · Seminars in Cancer Biology
14. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
    Jänne, Pasi A., Borras, Ana M., Kuang, Yanan, Rogers, Andrew M., Joshi, Victoria A., Liyanage, Hema, Lindeman, Neal, Lee, Jeffrey C., Halmos, Balazs, Maher, Elizabeth A. et al. · 2006 · Clinical Cancer Research
15. Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
    Harari, Paul M., Allen, Gregory W., Bonner, James A. · 2007 · Journal of Clinical Oncology
16. EGFR Mutations in Lung Adenocarcinomas
    Allan R. Li, Dhananjay Arun Chitale, Gregory J. Riely, William J. Pao, Vincent A. Miller, Maureen Frances Zakowski, Valerie W. Rusch, Mark G. Kris, Marc Ladanyi · 2008 · Journal of Molecular Diagnostics
17. Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method
    William J. Pao, Marc Ladanyi · 2007 · Clinical Cancer Research
18. Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells
    Tianhong Li, Yi‐He Ling, I. David Goldman, Roman Perez-Soler · 2007 · Clinical Cancer Research
19. Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study
    Lucio Crinò, Federico Cappuzzo, Petr Zatloukal, Martin Reck, Miloš Pešek, Joyce Thompson, Hugo E. R. Ford, Fred R. Hirsch, Marileila Varella‐Garcia, Serban Ghiorghiu et al. · 2008 · Journal of Clinical Oncology
20. Osimertinib-Induced Cardiotoxicity
    Kartik Anand, Joe Ensor, Barry H. Trachtenberg, Eric Bernicker · 2019 · JACC CardioOncology
21. Membrane‐anchored growth factors, the epidermal growth factor family: Beyond receptor ligands
    Shigeki Higashiyama, Hidehiko Iwabuki, Chie Morimoto, Miki Hieda, Hirofumi Inoue, Natsuki Matsushita · 2008 · Cancer Science
22. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate
    Alexander J J Smits, Jean Alain Kummer, Peter C. de Bruin, Mijke Bol, Jan G. van den Tweel, Kees A. Seldenrijk, Stefan M. Willems, G. Johan A. Offerhaus, Roel A. de Weger, P. J. van Diest et al. · 2013 · Modern Pathology
23. Quantification of Epidermal Growth Factor Receptor Expression Level and Binding Kinetics on Cell Surfaces by Surface Plasmon Resonance Imaging
    Fenni Zhang, Shaopeng Wang, Linliang Yin, Yunze Yang, Yan Guan, Wei Wang, Han Xu, Nongjian J. Tao · 2015 · Analytical Chemistry
24. Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L, Brenton, James D · 2011 · The Lancet Oncology
25. Surface enhanced Raman spectroscopy and its application to molecular and cellular analysis
    Yun Suk Huh, Aram J. Chung, David Erickson · 2009 · Microfluidics and Nanofluidics
26. Epidermal Growth Factor Receptor Signaling Synergizes with Hedgehog/GLI in Oncogenic Transformation via Activation of the MEK/ERK/JUN Pathway
    Harald Schnidar, Markus Eberl, Stefan Klingler, Doris Mangelberger, Maria Kasper, Cornelia Hauser‐Kronberger, Gerhard Regl, Renate Kroismayr, Richard Moriggl, Maria Chiara Sibilia et al. · 2009 · Cancer Research
27. Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features
    Karin E. Finberg, Lecia Van Dam Sequist, Victoria A. Joshi, Alona Muzikansky, Julie M. Miller, Moonjoo Han, Javad Beheshti, Lucian R. Chirieac, Eugene Jerome Mark, Anthony John Iafrate · 2007 · Journal of Molecular Diagnostics
28. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
    Naidoo, Jarushka, Sima, Camelia S., Rodriguez, Katherine, Busby, Natalie, Nafa, Khedoudja, Ladanyi, Marc, Riely, Gregory J., Kris, Mark G., Arcila, Maria E., Yu, Helena A. · 2015 · Cancer
29. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Enrico Franceschi, G Cavallo, Sara Lonardi, Elisabetta Magrini, A. Tosoni, Domenico Grosso, Luciano Scopece, Valeria Blatt, Benedetta Urbini, Andrea Pession et al. · 2007 · British Journal of Cancer
30. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
    Chien‐Hung Gow, Yih‐Leong Chang, Y.-C. Hsu, M.-F. Tsai, Chen‐Tu Wu, Chong‐Jen Yu, James Chih‐Hsin Yang, Yi‐Chia Lee, Pan‐Chyr Yang, Jin‐Yuan Shih · 2008 · Annals of Oncology
31. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
    Ebi, Hiromichi, Corcoran, Ryan B., Singh, Anurag, Chen, Zhao, Song, Youngchul, Lifshits, Eugene, Ryan, David P., Meyerhardt, Jeffrey A., Benes, Cyril, Settleman, Jeffrey et al. · 2011 · Journal of Clinical Investigation
32. Molecular biology of lung cancer: Clinical implications
    Kwun Meng Fong, John Dorrance Minna · 2002 · Clinics in Chest Medicine
33. AKT crystal structure and AKT-specific inhibitors
    C. Chandra Kumar, Vincent Madison · 2005 · Oncogene
34. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization
    Tara L. Naylor, Joel D. Greshock, Yan Wang, Theresa A. Colligon, Qian‐Chun Yu, Virginia B. Clemmer, Tal Z. Zaks, Barbara L. Weber · 2005 · Breast Cancer Research
35. Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
    Ernest Ramsay Camp, Justin M. Summy, Todd W. Bauer, Wenbiao Liu, Gary E. Gallick, Lee M. Ellis · 2005 · Clinical Cancer Research
36. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
    Neelu Puri, Ravi Salgia · 2008 · Journal of Carcinogenesis
37. Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
    Federico Cappuzzo, Claudia Ligorio, Pasi Antero Janne, Luca Toschi, Elisa Rossi, Rocco Trisolini, Daniela Paioli, Alison Holmes Tisch, Elisabetta Magrini, Giovanna Finocchiaro et al. · 2007 · Journal of Clinical Oncology
38. Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas
    DuyKhanh P. Ceppa, Mark G. Kris, Gregory J. Riely, Inderpal S. Sarkaria, Tiffani L. McDonough, Shaokun Chuai, Ennapadam S. Venkatraman, Vincent A. Miller, Marc Ladanyi, William J. Pao et al. · 2006 · Journal of Clinical Oncology
39. A method of high-throughput functional evaluation of <i>EGFR</i> gene variants of unknown significance in cancer
    Kohsaka, Shinji, Nagano, Masaaki, Ueno, Toshihide, Suehara, Yoshiyuki, Hayashi, Takuo, Shimada, Naoko, Takahashi, Kazuhisa, Suzuki, Kenji, Takamochi, Kazuya, Takahashi, Fumiyuki et al. · 2017 · Science Translational Medicine
40. Pathogenesis of lung cancer signalling pathways: roadmap for therapies
    Elisabeth M. Brambilla, Adi F. Gazdar · 2009 · European Respiratory Journal
41. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
    Kōichi Goto, Yukito Ichinose, Yuichiro Ohe, Nobuyuki Yamamoto, Shunichi Negoro, Kazuto Nishio, Yohji Itoh, Haiyi Jiang, Emma L. Duffield, Rose McCormack et al. · 2011 · Journal of Thoracic Oncology
42. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
    Eugene M. Tulchinsky, Oleg N. Demidov, Marina V. Kriajevska, Nickolai A. Barlev, Евгений Наумович Имянитов · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
43. Lung cancer in never smokers—the East Asian experience
    Fei Zhou, Caicun Zhou · 2018 · Translational Lung Cancer Research
44. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S.W. Tan, Suresh S. Ramalingam, Caicun Zhou · 2024 · Nature Reviews Clinical Oncology
45. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology
    Donal J. Brennan, Darran P. O’Connor, Elton Rexhepaj, Fredrik Pontén, William M. Gallagher · 2010 · Nature reviews. Cancer
46. Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
    Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Sohei Nakayama, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shinnosuke Ikemura, Takashi Sato et al. · 2013 · Molecular Cancer Research
47. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping‐Chih Hsu, David M. Jablons, Cheng‐Ta Yang, Liang You · 2019 · International Journal of Molecular Sciences
48. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study
    Harris, Marian H., DuBois, Steven G., Glade Bender, Julia L., Kim, AeRang, Crompton, Brian D., Parker, Erin, Dumont, Ian P., Hong, Andrew L., Guo, Dongjing, Church, Alanna et al. · 2016 · JAMA Oncology
49. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
    Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A. et al. · 2018 · Clinical Cancer Research
50. Cancer Biomarkers—An Invitation to the Table
    William S. Dalton, Stephen Henry Friend · 2006 · Science
51. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
    Hongdo Do, Michael Krypuy, Paul L R Mitchell, Stephen B. Fox, Alexander Dobrovic · 2008 · BMC Cancer
52. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
    Thomas John, Geoffrey Liu, Ming‐Sound Tsao · 2009 · Oncogene
53. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
    Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan, Ultan McDermott, Jennifer A. Lamb, Shyamala Maheswaran, Jeffrey E. Settleman, Daniel A. Haber · 2008 · Molecular Cancer Therapeutics
54. High-throughput Phenotyping of Lung Cancer Somatic Mutations
    Alice H. Berger, Angela Norie Brooks, Xiaoyun Wu, Yashaswi Shrestha, Candace R. Chouinard, Federica Piccioni, Mukta Bagul, Atanas Kamburov, Marcin B. Imielinski, Larson J. Hogstrom et al. · 2016 · Cancer Cell
55. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
    Mengzhu Zheng, Junfeng Huo, Xiaoxia Gu, Yali Wang, Canrong Wu, Qingzhe Zhang, Wancong Wang, Yang Liu, Yu Liu, Xuechen Zhou et al. · 2021 · Journal of Medicinal Chemistry
56. Pharmacological targeting of the pseudokinase Her3
    Xie, Ting, Lim, Sang Min, Westover, Kenneth D, Dodge, Michael E, Ercan, Dalia, Ficarro, Scott B, Udayakumar, Durga, Gurbani, Deepak, Tae, Hyun Seop, Riddle, Steven M et al. · 2014 · Nature Chemical Biology
57. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
    Kenneth John O'Byrne, Ulrich Gatzemeier, Igor Bondarenko, Carlos H. Barrios, Corinna Eschbach, Uwe M. Martens, Yevhen Hotko, C. Kortsik, Luis G Paz-Ares, Jose R. Pereira et al. · 2011 · The Lancet Oncology
58. Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
    Young-Wook Kim, Peter S. Hammerman, Jaegil Kim, Ji-ae Yoon, Yoomi Lee, Jong‐Mu Sun, Matthew D. Wilkerson, Chandra Sekhar Pedamallu, Kristian Cibulskis, Yeong Kyung Yoo et al. · 2013 · Journal of Clinical Oncology
59. Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
    Watanabe, Satoshi, Minegishi, Yuji, Yoshizawa, Hirohisa, Maemondo, Makoto, Inoue, Akira, Sugawara, Shunichi, Isobe, Hiroshi, Harada, Masao, Ishii, Yoshiki, Gemma, Akihiko et al. · 2014 · Journal of Thoracic Oncology
60. FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
    Rebecca Suk Heist, Mari A. Mino-Kenudson, Lecia Van Dam Sequist, Swathi Tammireddy, Laura Morrissey, David C. Christiani, Jeffrey A. Engelman, Anthony John Iafrate · 2012 · Journal of Thoracic Oncology
61. Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study
    Anne Mc Leer, Denis Moro‐Sibilot, A. Melis, Dimitri Salameire, Christine Lefebvre, Françoise Ceccaldi, Florence de Fraipont, Elisabeth M. Brambilla, Sylvie Lantuéjoul · 2011 · Journal of Thoracic Oncology
62. Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition
    K.S. Gajiwala, Junli Feng, Rose Ann Ferre, Kevin Ryan, Oleg Brodsky, Scott L. Weinrich, John C. Kath, Albert Stewart · 2012 · Structure
63. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
    Kenichi Suda, Isao Murakami, Tatsuya Katayama, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yoshihiko Maehara, Yasushi Yatabe, Tetsuya Mitsudomi · 2010 · Clinical Cancer Research
64. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
    Jimmy A. Blair, Daniel Rauh, Charles K.-H. Kung, Cai‐Hong Yun, Qi-Wen Fan, Haridas B. Rode, Chao Zhang, Michael J. Eck, William A. Weiss, Kevan M. Shokat · 2007 · Nature Chemical Biology
65. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
    Giuseppe Giaccone · 2005 · Journal of Clinical Oncology
66. Drivers and passengers
    Daniel A. Haber, Jeff Settleman · 2007 · Nature
67. New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
    Mizuki Nishino, David Michael Jackman, Hiroto Hatabu, Beow Yong Yeap, Leigh‐Anne Cioffredi, Jeffrey T. Yap, Pasi Antero Janne, Bruce Evan Johnson, Annick D. Van den Abbeele · 2010 · American Journal of Roentgenology
68. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
    Daniel S.W. Tan, Tony S.K. Mok, Timothy Richard Rebbeck · 2015 · Journal of Clinical Oncology
69. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications
    Federica Zito Marino, Roberto Bianco, Marina Accardo, Andrea Ronchi, Immacolata Cozzolino, Floriana Morgillo, Giulio Rossi, Renato Franco · 2019 · International Journal of Medical Sciences
70. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies
    Christopher M. Aldrighetti, Andrzej Niemierko, Eliezer M. Van Allen, Henning Willers, Sophia C. Kamran · 2021 · JAMA Network Open
71. Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for Survival
    Lanxi Song, Mark D. Morris, Tapan Kumar Bagui, Francis Y. Lee, Richard Jove, Eric B. Haura · 2006 · Cancer Research
72. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    Aristea Kalikaki, Anastasios V. Koutsopoulos, Maria Trypaki, John Souglakos, Efstathios N. Stathopoulos, Vassilis Georgoulias, D. Mavroudis, Alexandra Voutsina · 2008 · British Journal of Cancer
73. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies
    Hester van Cruijsen, Giuseppe Giaccone, Klaas Hoekman · 2005 · International Journal of Cancer
74. Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
    Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, Maria Catherine Pietanza, Maureen Frances Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi et al. · 2011 · Molecular Cancer Therapeutics
75. Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors
    Helen C. Su, Claudia Bodenstein, Rebecca A. Dumont, Yann Seimbille, Steven M. Dubinett, Michael E. Phelps, Harvey R. Herschman, Johannes G. Czernin, Wolfgang Weber · 2006 · Clinical Cancer Research
76. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
    Linnéa La Fleur, Elin Falk-Sörqvist, Patrik Smeds, Anders Berglund, Magnus Sundström, Johanna SM Mattsson, Eva Brandén, Hirsh Koyi, Johan Isaksson, Hans Brunnström et al. · 2019 · Lung Cancer
77. Cell-free DNA analysis in current cancer clinical trials: a review
    Mireya Cisneros-Villanueva, Lizbett Hidalgo Pérez, Magdalena Ríos-Romero, Alberto Cedro‐Tanda, C. A. Ruiz-Villavicencio, K. Page, Robert K. Hastings, Daniel Fernández-García, Rebecca C. Allsopp, Marco Antonio Fonseca-Montaño et al. · 2022 · British Journal of Cancer
78. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
    Qing Wu, Wei Qian, Xiaoli Sun, Shaojie Jiang · 2022 · Journal of Hematology & Oncology
79. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
    Tan, Daniel S.W., Yom, Sue S., Tsao, Ming S., Pass, Harvey I., Kelly, Karen, Peled, Nir, Yung, Rex C., Wistuba, Ignacio I., Yatabe, Yasushi, Unger, Michael et al. · 2016 · Journal of Thoracic Oncology
80. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
    Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii, Shunichi Negoro, T. Hirashima, Satoshi Kudoh, Y. Ichinose, Noriyuki Ebi, Kazuhiko Shibata, Takashi Nishimura et al. · 2008 · British Journal of Cancer
81. New molecularly targeted therapies for lung cancer
    Sophie Sun, Joan H. Schiller, Monica Spinola, John Dorrance Minna · 2007 · Journal of Clinical Investigation
82. Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
    Endang R. Purba, Ei‐ichiro Saita, ICHIRO N. MARUYAMA · 2017 · Cells
83. In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung Adenocarcinoma
    Fei Li, Qingyuan Huang, Troy A. Luster, Hai Hu, Hua Zhang, Wai‐Lung Ng, Alireza Khodadadi‐Jamayran, Wei Wang, Ting Chen, Jiehui Deng et al. · 2019 · Cancer Discovery
84. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
    K. Tsuta, Takashi Kohno, Akihiko Yoshida, Yoko Shimada, Hisao Asamura, Koh Furuta, Ryoji Kushima · 2014 · British Journal of Cancer
85. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
    Hideharu Kimura, Mika Suminoe, Kazuo Kasahara, T. Sone, Tomoyuki Araya, Shunichi Tamori, Fumiaki Koizumi, Kazuto Nishio, K Miyamoto, M Fujimura et al. · 2007 · British Journal of Cancer
86. Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
    Jeet Gandhi, Jianling Zhang, Yang Xie, Junichi Soh, Hisayuki Shigematsu, Wei Zhang, Hiromasa Yamamoto, Michael Peyton, Luc Girard, William Wirt Lockwood et al. · 2009 · PLoS ONE
87. Worldwide Frequency of Commonly Detected EGFR Mutations
    Rondell Patrell Graham, Amanda L. Treece, Neal Ian Lindeman, Patricia Vasalos, Mu Shan, Lawrence J. Jennings, David L. Rimm · 2017 · Archives of Pathology & Laboratory Medicine
88. Influence of Chemotherapy on <i>EGFR</i> Mutation Status Among Patients With Non–Small-Cell Lung Cancer
    Bai, Hua, Wang, Zhijie, Chen, Keneng, Zhao, Jun, Lee, J. Jack, Wang, Shuhang, Zhou, Qinghua, Zhuo, Minglei, Mao, Li, An, Tongtong et al. · 2012 · Journal of Clinical Oncology
89. Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study
    Giuseppe Giaccone, Marielle I. Gallegos Ruiz, Thierry Le Chevalier, N. Thatcher, Egbert Frederik Smit, José Antonio Rodríguez, Pasi Antero Janne, D. Oulid-Aïssa, Jean‐Charles Soria · 2006 · Clinical Cancer Research
90. A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
    Nathan A. Pennell, Gilbert H. Daniels, Robert I. Haddad, Douglas S. Ross, Tracey L. Evans, Lori J. Wirth, Panos Fidias, Jennifer S. Temel, Sarada Gurubhagavatula, Rebecca Suk Heist et al. · 2007 · Thyroid
91. Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
    Katsuhiro Okuda, Hidefumi Sasaki, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii · 2008 · Cancer Science
92. Assessment of Epidermal Growth Factor Receptor Mutation by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
    Takahiro Nakajima, Kazuhiro Yasufuku, Makoto Suzuki, Kenzo Hiroshima, Rieko Kubo, Sherif Mohammed, Yohei Miyagi, Shoichi Matsukuma, Yasuo Sekine, Takehiko Fujisawa · 2007 · CHEST Journal
93. Ligand-Independent EGFR Signaling
    Gao Guo, Ke Gong, Bryan Wohlfeld, Kimmo J. Hatanpaa, Dawen Zhao, Amyn A. Habib · 2015 · Cancer Research
94. Cancer biomarker discovery and translation: proteomics and beyond
    Ventzislava A. Hristova, Daniel W. Chan · 2018 · Expert Review of Proteomics
95. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
    Yuxin Lin, Xian Wang, Hongchuan Jin · 2014 · Europe PMC (PubMed Central)
96. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective
    Lawrence J. Lesko, Janet Woodcock · 2004 · Nature Reviews Drug Discovery
97. EGFR-mutated lung cancer: a paradigm of molecular oncology
    Zhang, Zhenfeng, Stiegler, Amy L., Boggon, Titus J., Kobayashi, Susumu, Halmos, Balazs · 2010 · Oncotarget
98. Treatment of Stage IV Non-small Cell Lung Cancer
    Mark A. Socinski, Tracey L. Evans, Scott N. Gettinger, Thomas A. Hensing, Lecia Van Dam Sequist, Belinda K. Ireland, Thomas E. Stinchcombe · 2013 · CHEST Journal
99. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
    Yuankai Shi, Junling Li, Shucai Zhang, Mengzhao Wang, Shujun Yang, Ning Li, Gang Wu, Wei Liu, Guoqing Liao, Kaican Cai et al. · 2015 · PLoS ONE
100. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
     Meng Cheng, Xufen Yu, Kaylene J. Lu, Ling Xie, Li Wang, Fanye Meng, Xiaoran Han, Xian Chen, Jing Liu, Yue Xiong et al. · 2020 · Journal of Medicinal Chemistry